This news item reports results of the phase III INTerpath-0001 trial in patients whose melanoma had been surgically removed. The trial added intismeran autogene, an individualised mRNA neoantigen vaccine, to the PD-1 inhibitor pembrolizumab. The comparison was against adjuvant pembrolizumab alone. The combination reduced the risk of disease recurrence or death by 42%. The results were presented at the ESMO Congress 2026 in Madrid. The abstract gives no sample size, follow-up time, confidence interval or overall survival data.
Why it is interesting: An individualised mRNA vaccine shows a 42% reduction in recurrence or death in a phase III adjuvant trial. The vaccine is built from each patient's own tumour neoantigens.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.
Other drivers in Tomorrow's world
-
Innovation in treatment
Treatments that did not exist before — drugs, operations, devices — and whether they reach the people who would benefit.
4 this week -
Changing behaviour at scale
Whether new technology can change what people do at the scale of a population: apps, wearables, automated messages, digital programmes and platforms, and how far their effects last and reach.
1 this week -
Medicine at a distance
What wearables, remote monitoring and care at home add to how health is measured and delivered, and whether it shows in outcomes.
1 this week -
A changing climate
How air pollution, heat and cold affect deaths and survival, how the attribution is made, and how the balance is changing.
2 this week -
Slowing ageing itself
Whether anything yet slows ageing itself, rather than treating one disease at a time, and how we would know if it did.
2 this week
